A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.
D. D. Von Hoff
Research Funding - Genentech
P. LoRusso
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
G. D. Demetri
Consultant or Advisory Role - EMD Serono; Genentech; GlaxoSmithKline; Kolltan Pharmaceuticals; Novartis; Pfizer; Plexxikon
Stock Ownership - Kolltan Pharmaceuticals; Plexxikon
Research Funding - Genentech; Novartis; Pfizer
G. J. Weiss
Research Funding - Genentech
G. Shapiro
Consultant or Advisory Role - Genentech
Research Funding - Genentech
R. K. Ramanathan
No relevant relationships to disclose
J. A. Ware
Employment or Leadership Position - Genentech
Stock Ownership - Roche
R. Raja
Employment or Leadership Position - Genentech
Stock Ownership - Roche
J. Jin
Employment or Leadership Position - Genentech
Stock Ownership - Roche
G. G. Levy
Employment or Leadership Position - Genentech
Stock Ownership - Roche
K. E. Mazina
Employment or Leadership Position - Genentech
Stock Ownership - Roche
A. J. Wagner
Consultant or Advisory Role - Genentech; Genentech; Infinity; Infinity; Novartis; Novartis
Honoraria - Novartis
Research Funding - Genentech